Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Varsha Gandhi, PhD, on Ibrutinib

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Sep

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

New ACS Prostate Cancer Report: Late-Stage Incidence Rates Continue to Increase Rapidly as Mortality Declines Slow

How a Novel Coaching Intervention Is Building Resilience and Hope in Adolescents and Young Adults With Advanced Cancer

Viral Immunotherapy May Extend Survival in Advanced NSCLC After Progression on Immune Checkpoint Inhibition

Surgical Resection With EGFR TKI Demonstrates Promising PFS in EGFR-Mutant NSCLC

Cardiotoxicity From the Use of Anthracyclines in Cancer Survivors: Preventive Strategies